AAAAI: Omalizumab Superior to Oral Immunotherapy in Multifood Allergy

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

MONDAY, March 3, 2025 -- Omalizumab is superior to oral immunotherapy (OIT) for multifood allergy, and most patients include dietary consumption (DC) of allergy-triggering foods after gaining tolerance, according to two studies presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology, held from Feb. 28 to March 3 in San Diego.

Robert Wood, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues compared omalizumab to OIT for multifood allergy in a randomized double-blind trial (OUtMATCH). All 117 participants received 16 weeks of open-label omalizumab; at week 9, OIT/placebo-OIT was initiated. Participants transitioned to blinded injection therapy (omalizumab or placebo) at week 16 for 44 weeks before being rechallenged. The researchers found that in the intent-to-treat analysis, omalizumab was superior for the primary end point of tolerance of ≥2,000 mg for all three foods (success, 36 versus 19 percent; odds ratio, 2.6).

Jennifer Dantzer, M.D., also from the Johns Hopkins University School of Medicine, and colleagues examined the introduction of allergenic foods after completing the placebo-controlled stage 1 of OUtMATCH. The first 60 participants entered a 24-week open-label omalizumab extension, followed by stage 3, off omalizumab, which could include DC, rescue OIT, or food avoidance. The researchers found that most (82 percent) of the initial treatment plans included DC. Success was defined as median daily consumption of ≥300 mg food protein by quarterly intervals over 12 months for those who started DC; success was higher for milk/egg/wheat than peanut/tree nuts (61 to 70 percent versus 38 to 56 percent).

"While the results of stage 3 are still preliminary, the majority of the first 60 participants were able to successfully introduce allergenic foods into their diet after stopping omalizumab," Dantzer said in a statement.

The study was funded by Genentech and Novartis. Genentech supplied omalizumab for the trial.

Abstract L48

Abstract L50

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-04 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords